data_1mp6_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1mp6 _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.522 3.143 0 N-CA-C 114.16 1.17 . . . . 0.0 114.16 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . . . -66.08 -34.64 78.54 Favored 'General case' 0 C--N 1.348 0.536 0 O-C-N 118.807 -2.433 . . . . 0.0 113.843 -173.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . . . -72.46 -51.18 7.59 Favored Pre-proline 0 CA--C 1.55 0.944 0 CA-C-O 117.745 -1.121 . . . . 0.0 111.62 173.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . . . -61.54 -32.2 87.82 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 CA-C-N 123.486 2.281 . . . . 0.0 117.356 174.564 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . . . -67.96 -47.19 69.3 Favored 'General case' 0 C--N 1.349 0.579 0 CA-C-N 120.378 1.444 . . . . 0.0 112.095 -179.672 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . . . -63.09 -39.96 87.23 Favored 'Isoleucine or valine' 0 C--N 1.356 0.859 0 CA-C-O 121.632 0.729 . . . . 0.0 112.114 178.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . . . -60.57 -48.4 88.72 Favored 'Isoleucine or valine' 0 C--N 1.355 0.836 0 O-C-N 120.733 -1.23 . . . . 0.0 112.651 173.373 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -57.25 -47.42 81.44 Favored 'General case' 0 C--N 1.358 0.935 0 O-C-N 120.818 -1.176 . . . . 0.0 113.734 176.542 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.73 -41.98 87.72 Favored 'General case' 0 C--N 1.347 0.498 0 C-N-CA 125.168 1.387 . . . . 0.0 112.73 176.32 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . . . -62.39 -46.67 87.55 Favored 'General case' 0 C--N 1.348 0.533 0 C-N-CA 124.112 0.965 . . . . 0.0 112.912 177.34 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . . . -60.4 -43.46 94.02 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.844 0 C-N-CA 124.615 1.166 . . . . 0.0 112.293 175.433 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . . . -59.01 -49.26 83.89 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.222 0 CA-C-N 113.855 -1.52 . . . . 0.0 113.337 176.193 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -56.64 -45.61 90.11 Favored Glycine 0 C--N 1.352 1.444 0 O-C-N 121.297 -0.877 . . . . 0.0 115.189 174.453 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . . . -59.64 -48.27 88.02 Favored 'Isoleucine or valine' 0 C--N 1.349 0.573 0 N-CA-C 112.941 0.719 . . . . 0.0 112.941 176.261 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . . . -57.08 -46.99 82.08 Favored 'General case' 0 C--N 1.355 0.843 0 O-C-N 120.69 -1.256 . . . . 0.0 113.541 175.297 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . . . -57.98 -47.3 83.4 Favored 'General case' 0 C--N 1.351 0.65 0 N-CA-C 113.749 1.018 . . . . 0.0 113.749 174.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . . . -57.73 -47.27 82.93 Favored 'General case' 0 C--N 1.348 0.501 0 O-C-N 120.786 -1.196 . . . . 0.0 113.825 175.219 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . . . -57.11 -47.7 83.34 Favored 'Isoleucine or valine' 0 C--N 1.351 0.673 0 C-N-CA 124.373 1.069 . . . . 0.0 112.747 174.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . . . -57.09 -47.12 81.81 Favored 'General case' 0 C--N 1.348 0.539 0 N-CA-C 112.986 0.736 . . . . 0.0 112.986 174.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . . . -58.34 -46.28 86.55 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.147 0.979 . . . . 0.0 113.542 176.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . . . -59.65 -42.18 87.59 Favored 'Isoleucine or valine' 0 C--N 1.349 0.575 0 C-N-CA 125.649 1.58 . . . . 0.0 112.122 175.077 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . . . -62.89 -39.76 95.48 Favored 'General case' 0 C--N 1.35 0.587 0 O-C-N 120.355 -1.466 . . . . 0.0 112.983 175.342 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . . . -64.59 -41.29 96.34 Favored 'General case' 0 C--N 1.349 0.585 0 N-CA-C 114.28 1.215 . . . . 0.0 114.28 172.462 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . . . -64.92 -36.27 83.82 Favored 'General case' 0 C--N 1.347 0.471 0 O-C-N 120.973 -1.079 . . . . 0.0 113.543 176.42 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.506 0 O-C-N 120.688 -1.258 . . . . 0.0 112.421 176.818 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.522 3.143 0 N-CA-C 114.16 1.17 . . . . 0.0 114.16 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . . . -66.08 -34.64 78.54 Favored 'General case' 0 C--N 1.348 0.536 0 O-C-N 118.807 -2.433 . . . . 0.0 113.843 -173.815 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . . . -72.46 -51.18 7.59 Favored Pre-proline 0 CA--C 1.55 0.944 0 CA-C-O 117.745 -1.121 . . . . 0.0 111.62 173.832 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . . . -61.54 -32.2 87.82 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 CA-C-N 123.486 2.281 . . . . 0.0 117.356 174.564 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . . . -67.96 -47.19 69.3 Favored 'General case' 0 C--N 1.349 0.579 0 CA-C-N 120.378 1.444 . . . . 0.0 112.095 -179.672 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . . . -63.09 -39.96 87.23 Favored 'Isoleucine or valine' 0 C--N 1.356 0.859 0 CA-C-O 121.632 0.729 . . . . 0.0 112.114 178.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . . . -60.57 -48.4 88.72 Favored 'Isoleucine or valine' 0 C--N 1.355 0.836 0 O-C-N 120.733 -1.23 . . . . 0.0 112.651 173.373 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -57.25 -47.42 81.44 Favored 'General case' 0 C--N 1.358 0.935 0 O-C-N 120.818 -1.176 . . . . 0.0 113.734 176.542 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.73 -41.98 87.72 Favored 'General case' 0 C--N 1.347 0.498 0 C-N-CA 125.168 1.387 . . . . 0.0 112.73 176.32 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . . . -62.39 -46.67 87.55 Favored 'General case' 0 C--N 1.348 0.533 0 C-N-CA 124.112 0.965 . . . . 0.0 112.912 177.34 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . . . -60.4 -43.46 94.02 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.844 0 C-N-CA 124.615 1.166 . . . . 0.0 112.293 175.433 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . . . -59.01 -49.26 83.89 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.222 0 CA-C-N 113.855 -1.52 . . . . 0.0 113.337 176.193 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -56.64 -45.61 90.11 Favored Glycine 0 C--N 1.352 1.444 0 O-C-N 121.297 -0.877 . . . . 0.0 115.189 174.453 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . . . -59.64 -48.27 88.02 Favored 'Isoleucine or valine' 0 C--N 1.349 0.573 0 N-CA-C 112.941 0.719 . . . . 0.0 112.941 176.261 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . . . -57.08 -46.99 82.08 Favored 'General case' 0 C--N 1.355 0.843 0 O-C-N 120.69 -1.256 . . . . 0.0 113.541 175.297 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . . . -57.98 -47.3 83.4 Favored 'General case' 0 C--N 1.351 0.65 0 N-CA-C 113.749 1.018 . . . . 0.0 113.749 174.91 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . . . -57.73 -47.27 82.93 Favored 'General case' 0 C--N 1.348 0.501 0 O-C-N 120.786 -1.196 . . . . 0.0 113.825 175.219 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . . . -57.11 -47.7 83.34 Favored 'Isoleucine or valine' 0 C--N 1.351 0.673 0 C-N-CA 124.373 1.069 . . . . 0.0 112.747 174.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . . . -57.09 -47.12 81.81 Favored 'General case' 0 C--N 1.348 0.539 0 N-CA-C 112.986 0.736 . . . . 0.0 112.986 174.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . . . -58.34 -46.28 86.55 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.147 0.979 . . . . 0.0 113.542 176.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . . . -59.65 -42.18 87.59 Favored 'Isoleucine or valine' 0 C--N 1.349 0.575 0 C-N-CA 125.649 1.58 . . . . 0.0 112.122 175.077 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . . . -62.89 -39.76 95.48 Favored 'General case' 0 C--N 1.35 0.587 0 O-C-N 120.355 -1.466 . . . . 0.0 112.983 175.342 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . . . -64.59 -41.29 96.34 Favored 'General case' 0 C--N 1.349 0.585 0 N-CA-C 114.28 1.215 . . . . 0.0 114.28 172.462 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . . . -64.92 -36.27 83.82 Favored 'General case' 0 C--N 1.347 0.471 0 O-C-N 120.973 -1.079 . . . . 0.0 113.543 176.42 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.506 0 O-C-N 120.688 -1.258 . . . . 0.0 112.421 176.818 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.522 3.143 0 N-CA-C 114.16 1.17 . . . . 0.0 114.16 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . . . -66.08 -34.64 78.54 Favored 'General case' 0 C--N 1.348 0.536 0 O-C-N 118.807 -2.433 . . . . 0.0 113.843 -173.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . . . -72.46 -51.18 7.59 Favored Pre-proline 0 CA--C 1.55 0.944 0 CA-C-O 117.745 -1.121 . . . . 0.0 111.62 173.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . . . -61.54 -32.2 87.82 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 CA-C-N 123.486 2.281 . . . . 0.0 117.356 174.564 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . . . -67.96 -47.19 69.3 Favored 'General case' 0 C--N 1.349 0.579 0 CA-C-N 120.378 1.444 . . . . 0.0 112.095 -179.672 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . . . -63.09 -39.96 87.23 Favored 'Isoleucine or valine' 0 C--N 1.356 0.859 0 CA-C-O 121.632 0.729 . . . . 0.0 112.114 178.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . . . -60.57 -48.4 88.72 Favored 'Isoleucine or valine' 0 C--N 1.355 0.836 0 O-C-N 120.733 -1.23 . . . . 0.0 112.651 173.373 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -57.25 -47.42 81.44 Favored 'General case' 0 C--N 1.358 0.935 0 O-C-N 120.818 -1.176 . . . . 0.0 113.734 176.542 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.73 -41.98 87.72 Favored 'General case' 0 C--N 1.347 0.498 0 C-N-CA 125.168 1.387 . . . . 0.0 112.73 176.32 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . . . -62.39 -46.67 87.55 Favored 'General case' 0 C--N 1.348 0.533 0 C-N-CA 124.112 0.965 . . . . 0.0 112.912 177.34 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . . . -60.4 -43.46 94.02 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.844 0 C-N-CA 124.615 1.166 . . . . 0.0 112.293 175.433 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . . . -59.01 -49.26 83.89 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.222 0 CA-C-N 113.855 -1.52 . . . . 0.0 113.337 176.193 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -56.64 -45.61 90.11 Favored Glycine 0 C--N 1.352 1.444 0 O-C-N 121.297 -0.877 . . . . 0.0 115.189 174.453 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . . . -59.64 -48.27 88.02 Favored 'Isoleucine or valine' 0 C--N 1.349 0.573 0 N-CA-C 112.941 0.719 . . . . 0.0 112.941 176.261 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . . . -57.08 -46.99 82.08 Favored 'General case' 0 C--N 1.355 0.843 0 O-C-N 120.69 -1.256 . . . . 0.0 113.541 175.297 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . . . -57.98 -47.3 83.4 Favored 'General case' 0 C--N 1.351 0.65 0 N-CA-C 113.749 1.018 . . . . 0.0 113.749 174.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . . . -57.73 -47.27 82.93 Favored 'General case' 0 C--N 1.348 0.501 0 O-C-N 120.786 -1.196 . . . . 0.0 113.825 175.219 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . . . -57.11 -47.7 83.34 Favored 'Isoleucine or valine' 0 C--N 1.351 0.673 0 C-N-CA 124.373 1.069 . . . . 0.0 112.747 174.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . . . -57.09 -47.12 81.81 Favored 'General case' 0 C--N 1.348 0.539 0 N-CA-C 112.986 0.736 . . . . 0.0 112.986 174.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . . . -58.34 -46.28 86.55 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.147 0.979 . . . . 0.0 113.542 176.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . . . -59.65 -42.18 87.59 Favored 'Isoleucine or valine' 0 C--N 1.349 0.575 0 C-N-CA 125.649 1.58 . . . . 0.0 112.122 175.077 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . . . -62.89 -39.76 95.48 Favored 'General case' 0 C--N 1.35 0.587 0 O-C-N 120.355 -1.466 . . . . 0.0 112.983 175.342 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . . . -64.59 -41.29 96.34 Favored 'General case' 0 C--N 1.349 0.585 0 N-CA-C 114.28 1.215 . . . . 0.0 114.28 172.462 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . . . -64.92 -36.27 83.82 Favored 'General case' 0 C--N 1.347 0.471 0 O-C-N 120.973 -1.079 . . . . 0.0 113.543 176.42 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.506 0 O-C-N 120.688 -1.258 . . . . 0.0 112.421 176.818 . . . . . . . . 0 0 . 1 stop_ save_